Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of AZD5462 in Healthy Volunteers
NCT04994106Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2021
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of AZD5462 in heart failure (HF) (15 arms), sponsored by AstraZeneca. Primary endpoint: Number of Participants with Adverse Events at Day 19. Started Jul 2021; status: completed.
02
Drugs
AZD5462
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT04994106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04994106.